Lipocine’s (LPCN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Lipocine (NASDAQ:LPCN) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $8.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright also issued estimates for Lipocine’s Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.39) EPS and Q4 2026 earnings at ($0.39) EPS.

Separately, Wall Street Zen started coverage on shares of Lipocine in a report on Saturday, May 17th. They set a “hold” rating for the company.

Lipocine Stock Performance

Shares of LPCN opened at $3.16 on Tuesday. Lipocine has a one year low of $2.68 and a one year high of $11.79. The firm has a market capitalization of $16.91 million, a price-to-earnings ratio of -4.16 and a beta of 1.34. The stock’s fifty day moving average is $3.26 and its 200-day moving average is $3.83.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.35 million.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC boosted its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.